8-K filing — OS Therapies Inc (OSTX)
Filed: 2026-08-21 AccNo: 0001213900-26-092651 Size: 603 KB Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits
Stocks · News reference
OS Therapies Requests FDA Type B Meeting To Review Its 2.5-Year OST-HER2 Overall Survival Data And To Confirm Alignment That 3-year Overall Survival Data Is A Clinical Endpoint
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
OS Therapies Enters Open Market Sale Agreement With Jefferies; May Offer Common Stock Up To $75M Through Jefferies
-SEC Filing
FDA Grants OS Therapies’ Requested Type C Statistical Methods Meeting To Review 2.5-Yr Overall Survival Data From Phase 2b Trial Of OST-HER2 In Prevention Of Recurrence In Pulmonary Metastatic Osteosarcoma; Meeting To Occur In Mid-September
Meeting to occur in mid-September 2026Interim 3-year Overall Survival data expected early September, 2026Decisions on appropriate comparator arm to interpret OST-HER2 clinical efficacy, RMAT designation and Rolling
OS Therapies Terminates At Market Issuance Sales Agreement On July 23; Co. Announces Termination Of Sales Agreement Effective July 28